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Background: KRAS is an EGFR effector in the RAS/RAF/ERK cascade that is mutated in about 40% of metastatic
colorectal cancer (mCRC). Activating mutations in codons 12 and 13 of the KRAS gene are the only established
negative predictors of response to anti-EGFR therapy and patients whose tumors harbor such mutations are not
candidates for therapy. However, 40 to 60% of wild-type cases do not respond to anti-EGFR therapy, suggesting the
involvement of other genes that act downstream of EGFR in the RAS-RAF-MAPK and PI3K-AKT pathways or
activating KRAS mutations at other locations of the gene.
Methods: DNA was obtained from a consecutive series of 201 mCRC cases (FFPE tissue), wild-type for KRAS exon 2
(codons 12 and 13). Mutational analysis of KRAS (exons 3 and 4), BRAF (exons 11 and 15), and PIK3CA (exons 9 and 20)
was performed by high resolution melting (HRM) and positive cases were then sequenced.
Results: One mutation was present in 23.4% (47/201) of the cases and 3.0% additional cases (6/201) had two
concomitant mutations. A total of 53 cases showed 59 mutations, with the following distribution: 44.1% (26/59) in KRAS
(13 in exon 3 and 13 in exon 4), 18.6% (11/59) in BRAF (two in exon 11 and nine in exon 15) and 37.3%
(22/59) in PIK3CA (16 in exon 9 and six in exon 20). In total, 26.4% (53/201) of the cases had at least one mutation and
the remaining 73.6% (148/201) were wild-type for all regions studied. Five of the mutations we report, four in KRAS and
one in BRAF, have not previously been described in CRC. BRAF and PIK3CA mutations were more frequent in the colon
than in the sigmoid or rectum: 20.8% vs. 1.6% vs. 0.0% (P=0.000) for BRAF and 23.4% vs. 12.1% vs. 5.4% (P=0.011) for
PIK3CA mutations.
Conclusions: About one fourth of mCRC cases wild-type for KRAS codons 12 and 13 present other mutations either in
KRAS, BRAF, or PIK3CA, many of which may explain the lack of response to anti-EGFR therapy observed in a significant
proportion of these patients.Background
The increasing knowledge of cancer biology has led to the
development of targeted therapies, designed to interfere
with specific molecules involved in tumor growth and pro-
gression [1,2]. EGFR is a transmembrane receptor tyrosine
kinase (TK) implicated in several cellular responses, like
apoptosis, differentiation, cellular migration, and adhesion.* Correspondence: manuel.teixeira@ipoporto.min-saude.pt
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reproduction in any medium, provided the orThis TK and the pathways it controls play an important
role in colorectal carcinogenesis [3-5], making it a good
target for biological therapy of this disease [2]. A network
of various signal transduction cascades is stimulated by
EGFR signaling, namely the RAS/RAF/MEK/ERK,
PI3K/AKT, JAK/STAT and PLCγ pathways. Cetuximab,
a human-mouse chimeric IgG1, and panitumumab, a
fully human IgG2, are monoclonal antibodies (moABs)
that compete with EGFR’s ligands and specifically bind to
the receptor, blocking ligand-induced downstream signaling
[2]. These targeted agents have been evaluated in severall Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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cancer (mCRC), either alone, in combination with
fluoropyrimidine-based chemotherapy regimens, or with
bevacizumab [6-11], and have subsequently been approved
by the European Medicines Agency (EMEA) and the U.S.
Food and Drug Administration (FDA).
Several retrospective analyses of KRAS mutational
status in tumors from patients treated with cetuximab
and panitumumab found an association between KRAS
codons 12 or 13 activating mutations and lack of treatment
efficacy [6-11]. In normal cells, the KRAS protein alternates
between an inactive GDP-bound form and an active GTP-
bound form. Mutations in KRAS codons 12 and 13 origin-
ate a constitutively active protein, resulting in a continuous
and self-sufficient (independent of ligand binding) KRAS
signaling. These KRAS mutations, present in about 40%
of mCRC, are the only available (negative) predictors of
response to anti-EGFR moABs, and this therapy is
strictly indicated for patients with KRAS wild-type
mCRC [6,9,12,13]. However, absence of KRAS exon 2
mutations does not guarantee treatment response, as
only 40 to 60% of these cases respond to anti-EGFR
therapy [7,13,14]. Other mutations in genes encoding
proteins that act downstream of EGFR, such as KRAS,
BRAF, and PIK3CA, may be responsible for the absence
of treatment response in such cases.
In this study, 201 cases of mCRC wild-type for KRAS
codons 12 and 13 were screened for mutations in other
potential biomarkers of response to anti-EGFR treatment,
namely in the coding regions of KRAS switch II and G5
regions (exons 3 and 4), the P-loop and activation segment
of BRAF (exons 11 and 15), and in PIK3CA’s helical and
kinase domains (exons 9 and 20) [15,16].
Methods
Samples
A consecutive series of tumor samples (formalin-fixed
and paraffin-embedded, wild-type for KRAS codons 12
and 13) from 212 patients with stage IV colorectal
adenocarcinoma were retrospectively analyzed. These
patients were referred to the Genetics Department of
IPO-Porto, between August 2008 and January 2010, for
routine KRAS codons 12 and 13 mutation analysis and
were considered wild-type for both codons by at least
two of four independent methods in a previous work by
our group, representing 56.5% of the cases [17]. When
patients received neoadjuvant radiotherapy, diagnostic
tumor biopsies were used for mutation analyses instead
of primary tumors. Of these 212 cases, eight were
excluded due to lack/poor quality DNA and another
three because of missing clinical data. A total of 201 cases
were analyzed and their clinical characteristics are listed in
Additional File 1: Table S1. This study was approved by the
Institutional Review Board of the Portuguese OncologyInstitute-Porto and written informed consent was obtained
from all patients before testing.
DNA extraction
Hematoxylin and eosin (H&E) stained slides from tumors
of each case were reviewed by a pathologist, who delimited
areas containing at least 70% tumor cells. Unstained slides
were immersed in xylene for 5 minutes and twice in etha-
nol 100% for 5 minutes. Tumor areas were then delimited,
by comparison with correspondent H&E stained slides,
and macrodissected. DNA was isolated from scrapped
material using the methods described by Lungu et al.[18],
phenol-chlorophorm [19], or by the QIAampW DNA FFPE
TissueKit (QIAGEN, Hilden, Germany). DNA was quanti-
fied by spectrophotometry with NanoDrop ND-1000W
(Thermo Fisher Scientific Inc., Waltham, MA, USA).
Mutational analysis
We searched for mutations in KRAS mutational hotspots
other than exon 2 (NM_004985.3; exons 3 and 4), as well
as in BRAF (NM_004333.3; exons 11 and 15), and in
PIK3CA (NM_006218.2; exons 9 and 20). High resolution
melting (HRM) was used as a screening method to distin-
guish mutated from wild-type samples. DNA sequencing of
one strand was performed in those samples considered
positive by HRM. All mutated samples were subject to a
second HRM and DNA sequencing analyses in order to
validate the results.
PCR amplification and HRM were performed on a
LightCyclerW 480 II Real-Time System (Roche Diagnostics,
Basel, Switzerland). PCR mastermix containing one primer
pair, all PCR reagents, and DNA (Additional File 2:
Table S2) was added to each well of a 96 well plate. Fifteen
microliters of mineral oil were added to all wells in order
to prevent evaporation and cross-contamination. Plates
were sealed with sealing film and centrifuged at 2000 rpm
for 2 minutes. All samples were run in duplicate.
Primer pairs for KRAS exons 3 and 4 were designed
with primer-BLAST software (http://www.ncbi.nlm.nih.
gov/tools/primer-blast/; Additional File 3: Table S3).
Primer pairs for PIK3CA exons 9 and 20 and BRAF
exons 11 and 15 were previously described [20-22].
Cycling and melting conditions were as follows: an
initial denaturation at 95°C for 10 minutes followed by
40 cycles of 20 seconds at 90°C, 20 seconds at 67°C,
and 20 seconds at 72°C (for PIK3CA exons 9 and 20, BRAF
exon 11, and KRAS exon 3) or 40 cycles of 20 seconds at
95°C, 20 seconds at 65°C, and 20 seconds at 72°C
(for BRAF exon 15 and KRAS exon 4) and a final
extension at 72°C for 10 minutes. One heteroduplex
cycle was done at 95°C for 5 minutes and 40°C for
1 minute, followed by melting from 70°C to 90°C
with 25 acquisitions/°C and a 1 minute cooling to
40°C with a ramp rate of 2.2°C/second.
Guedes et al. BMC Cancer 2013, 13:169 Page 3 of 10
http://www.biomedcentral.com/1471-2407/13/169Amplification and melting curves were generated and
analyzed using the LightCyclerW 480 Gene Scanning
software version 1.5 (Roche diagnostics). Samples with
late amplification were excluded from the analysis. PCR
amplification products generated by the LightCycler PCR
were purified using illustra GFX PCR DNA and Gel Band
Purification Kit (GE Healthcare, Little Chalfont, UK)
according to the manufacturer’s protocol. For the se-
quencing reaction, 1 μL of purified PCR amplification
products were used with 1 μL of Big DyeW Terminator
V1.1 cycle sequencing Ready Reaction Mix (dNTPs.
ddNTPs-fluorocromes, MgCl2, Tris–HCl buffer), 1.9 μL
of Big DyeW Terminator V1.1, V1.3 5x sequencing buffer
(Applied Biosystems Inc., Fostercity, CA, USA), 350 nM of
primers described above and bidestilled sterile water to a
total volume of 10 μL. The sequencing reaction consisted of
an initial denaturation step at 96°C for 5 minutes, followed
by 35 cycles of 96°C for 10 seconds, 52°C for 5 seconds and
60°C for 4 minutes. Sequencing reaction products were
purified prior to sequencing in order to remove contami-
nants, using illustra SephadexW G-50 fine (GE Healthcare
Life Sciences). After purification, 12 μL of Hi-Di™
Formamide (Applied Biosystems) were added to the
sequencing product. Sequencing PCR products were
run on an ABI PRISM™ 310 Genetic Analyzer and
the respective electropherograms were analyzed with
Sequencing Analysis Software v5.2 (Applied Biosystems).
All electropherograms were read manually.
Statistical analysis
Chi-square or Fisher’s exact tests were performed as
appropriate to assess statistical differences between two
groups of patients, and linear-by-linear association was
used when comparing more than two sequential groups.
Associations were considered statistically significant
when P≤0.05. All statistical analyses were performed
with SPSS Statistics v.19 (SPSS Inc., IL, USA).
Results
Mutation frequencies
A total of 201 KRAS exon 2 wild-type mCRC samples
were screened by HRM for mutations in exons 3 and 4
of KRAS, exons 11 and 15 of BRAF, and exons 9 and 20
of PIK3CA (Figure 1). Subsequent automated sequencing
of HRM positive cases confirmed the presence of 59 mu-
tations in 53 cases, with the following distribution: 44.1%
(26/59) in KRAS (13 in exon 3 and 13 in exon 4), 18.6%
(11/59) in BRAF (two in exon 11 and nine in exon 15) and
37.3% (22/59) in PIK3CA (16 in exon 9 and six in exon 20).
One mutation was present in 23.4% (47/201) of the cases
and 3.0% additional cases (6/201) had two concomitant
mutations. In total, 26.4% (53/201) of the cases had at least
one mutation and the remaining 73.6% (148/201) were
wild-type for all regions studied. All mutations were foundin heterozygosity and were confirmed in a second HRM
and DNA sequence analysis.
Samples with single mutations were distributed as fol-
lows: 10.0% (20/201) were KRAS mutated, 5.0% (10/201) in
exon 3 and 5.0% (10/201) in exon 4; 5.0% (10/201) had one
BRAF mutation, 0.5% (1/201) in exon 11 and 4.5% (9/201)
in exon 15; 8.5% (17/201) were PIK3CA mutated, 7.0%
(14/201) in exon 9 and 1.5% (3/201) in exon 20 (Table 1).
Concomitant mutations were found with the following
distribution: 2.0% (4/201) of cases had simultaneous mu-
tations in PIK3CA and KRAS, 0.5% (1/201) in PIK3CA
and BRAF, and 0.5% (1/201) two mutations in KRAS
(Table 2). Of all mutations here reported, five have not
been previously described in colorectal cancer [23-25]:
two duplications, one deletion, and one point mutation
in KRAS and one point mutation in BRAF (Figure 2).
KRAS mutations
The eight KRAS codon 61 mutations present in our
series result in four different amino acid substitutions
(p.Gln61His, p.Gln61Lys, p.Gln61Leu, and p.Gln61Arg),
with the p.Gln61Leu being the most frequent codon 61
mutation in this series (37.5%; 3/8). Mutations found in
codon 146 were restricted to the p.Ala146Thr substitution.
Besides those in codons 61 and 146, other KRAS exon 3
mutations represented 19% (5/26) of all KRAS changes,
including one deletion (p.Ala59del), two point mutations
(p.Glu49Lys and p.Gly60Val) and two large in frame dupli-
cations (p.Cys51_Ser65dup and p.Thr58_Met72dup). Of
these five mutations, only p.Gly60Val has been recently
reported in CRC [26], whereas the other four are novel
mutations in CRC [23].
One of the cases carrying a KRAS p.Gln61His mutation
had a concomitant PIK3CA p.Glu542Lys substitution. The
p.Thr58_Met72dup duplication occurred in one tumor car-
rying a PIK3CA p.His1047Tyr substitution. Two tumors
with KRAS Ala146Thr mutations also had a PIK3CA muta-
tion, either p.Glu545Lys or p.His1046Arg. In addition, one
case harbored two KRAS mutations, namely p.Glu49Lys
and p.Ala146Thr.
BRAF mutations
The frequency of BRAF p.Val600Glu mutations found in
this series was 4.0% (8/201). This mutation represented
89% (8/9) of exon 15 mutations and 73% (8/11) of all
BRAF mutations. We also found mutations in codons 601
(p.Lys601Glu), 466 (p.Gly466Glu), and 471 (p.Val471Ala) of
BRAF, the latter not previously described in mCRC [23].
One BRAFmutation, p.Val471Ala, occurred in a tumor also
carrying a PIK3CA p.His1047Arg mutation.
PIK3CA
PIK3CA mutations were present in 10.9% (22/201)
of the tumors, unequally distributed between exons
Figure 1 High resolution melting analysis of PIK3CA exon 9. A) Normalized and B) difference graph, containing wild-type samples (blue) and
mutated samples (green and red).
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(p.Glu542Lys, p.Glu545Lys, p.Glu545Asp, and p.Gln546Lys)
and 27% (6/22) kinase domain mutants (p.Met1043Ile,
p.His1047Arg, p.His1047Leu, and p.His1047Tyr). Five
of the PIK3CA mutants also contained another muta-
tion in either KRAS or BRAF.
Clinicopathological associations
KRAS mutations were more frequent in patients older than
the median age of diagnosis (21.5% vs. 8.2%; P=0.034),
whereas no statistically significant differences were found
for BRAF or PIK3CA mutations regarding this parameter.BRAF and PIK3CA mutations were more frequent in
the colon than in the sigmoid or rectum: 20.8% vs. 1.6%
vs. 0.0% (P=0.000) for BRAF and 23.4% vs. 12.1% vs. 5.4%
(P=0.011) for PIK3CA mutations (Figure 3). Although the
frequency of KRAS mutations is higher in sigmoid and
rectum, the difference is not statistically significant. No
significant differences were found between genders
regarding KRAS, BRAF, or PIK3CA mutation frequencies.
Discussion
We here show that more than one-fourth of KRAS exon 2
wild-type mCRC patients present other mutations in KRAS,


















KRAS exon 4 c.436G>A p.Ala146Thr 10 10 (5.0%)
BRAF exon 11 c.1397G>A p.Gly466Glu 1 1 (0.5%)
BRAF exon 15 c.1799 T>A pVal600Glu 8 9 (4.5%)
c.1808A>G p.Lys601Glu 1




PIK3CA exon 20 c.3129G>A p.Met1043Ile 1 3 (1.5%)
c.3140A>G p.His1047Arg 1
c.3140A>T p.His1047Leu 1
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namely four in KRAS exon 3 and one in BRAF exon 11.
The mutational frequencies in the most commonly altered
codons of KRAS, BRAF, and PIK3CA genes were in accord-
ance to those previously described in the literature. We
have previously shown that HRM is a highly sensitive tech-
nique to detect mutations in mCRC, being significantlyTable 2 Frequency of double mutants (N=6/201)











PIK3CA exon 9 c.1633G>A p.Glu545Lys 1 6 (3.0%)
KRAS exon 4 c.436G>A p.Ala146Thr
PIK3CA exon 9 c.1624G>A p.Glu542Lys 1
KRAS exon 3 c.183A>C p.Gln61His
PIK3CA exon 20 c.3139C>T p.His1047Tyr 1
KRAS exon 3 c.173_217dup p.Thr58_Met72dup
PIK3CA exon 20 c.3140A>G p. His1047Arg 1
KRAS exon 4 c.436G>A p.Ala146Thr
PIK3CA exon 20 c.3140A>G p.His1047Arg 1
BRAF exon 11 c.1412 T>C p.Val471Ala
KRAS exon 3 c.145G>A p.Glu49Lys 1
KRAS exon 4 c.436G>A p.Ala146Thrmore sensitive and cheaper than standard Sanger sequen-
cing [17], combining high sensitivity with the ability to de-
tect novel mutations. A KRAS codon 61 and 146 mutation
frequency of 10.4% is similar to what has been reported for
KRAS codons 12 and 13 wild-type patients (6.5% - 10.5%)
[24,25]. The frequency of the BRAF p.Val600Glu mutation
was lower (4.0%) but comparable to the reported frequency
range of 4-18% in mCRC without KRAS codon 2 mutations
[25,27-30]. Since the BRAF p.Val600Glu mutation is associ-
ated with microsatellite instability (MSI) status and right
colon tumors [31-33], variations in sample characteristics
between studies can account for the wide frequency range,
but this is often hard to verify as many studies in mCRC do
not describe the primary tumor localization nor MSI status.
PIK3CA mutations were present in 10.9% of the tumors,
which is similar to previous reports [24,34-36]. Interest-
ingly, both BRAF (P=0.000) and PIK3CA (P=0.011) muta-
tions were significantly more frequent in colon than in
sigmoid or rectal carcinomas. On the other hand, an associ-
ation was found between KRAS mutations and older age at
diagnosis (P=0.034), which was not observed for BRAF or
PIK3CA. These findings should be confirmed in larger
series in order to evaluate its significance.
KRAS codon 61 oncogenic mutations occur at an
essential position for GTP hydrolysis and decrease RAS-
mediated GTP hydrolysis [37], resulting in transformation
efficiencies that vary up to 1000-fold [38]. It has been
demonstrated in vivo that codon 61Leu, Lys, and Arg in-
duce a strong oncogenic phenotype, whereas 61 His is a
moderately transforming mutant [38]. Aminoacid Ala146
is involved with guanine base interaction and mutations in
this codon do not affect GTPase activity, but are associ-
ated with an increased GDP to GTP exchange. Expression
of p.Ala146Thr mutations in vivo results in elevated RAS-
GTP and phosphorylated ERK compared to wild-type
KRAS, albeit lower than that caused by codon 12 muta-
tions [39]. However, there is no data available to deter-
mine the influence in RAS protein structure of the novel
deletion (p.Ala59del) and the two novel large in frame
duplications (p.Cys51_Ser65dup and p.Thr58_Met72dup)
we found in exon 3, but the fact that they are located in
the switch II region is an indicator that they may activate
RAS by impairing GTP hydrolysis. Of notice, few KRAS
duplications and deletions have been reported: only three
in exon 2 and two in exon 3. No functional studies exist
regarding the role of KRAS p.Gly60Val or p.Glu49Lys mu-
tations, but it is known that the Gly60 residue interacts
with γ-phosphate of GTP and is a conserved amino acid
in the superfamily of GTPases [40], facts that argue in
favor of Gly60Val pathogenicity.
Both BRAF p.Val600Glu and p.Lys601Glu mutations
occur in the activation site and originate proteins with
high kinase activity. In vitro, BRAF p.Val600Glu and
p.Lys601Glu proteins have higher TK activity than the
Figure 2 (See legend on next page.)
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Figure 2 Electropherograms of the novel mutations found in this series and of wild-type samples. A) and E) KRAS exon 3 wild-type
samples; B), C), D) and F) KRAS exon 3 mutations; G) BRAF exon 11 wild-type; H) BRAF exon 11 mutant sample. Fw: forward strand. Rev: reverse
strand. Arrow indicates the mutational spot.
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ively) [41]. Mutants p.Val600Glu also show a six-fold
higher ERK signaling in vivo, when compared to the
wild-type protein [41]. These high TK activity mutants
are thought to simulate the conformational changes
caused by activation segment phosphorylation, resulting
in protein ligand-independent constitutive activation. On
the other hand, the Gly466 is the second glycine of the
P-loop GXGXXG motif (G=glycine; X=variable), conserved
in more than 99% of all kinases [15]. It is an important
catalytic residue and its substitution to glutamic acid
(p.Gly466Glu) originates a protein with higher ERK
signaling than wild-type BRAF but a diminished, although
constitutively active, TK activity [41]. It has been proposed
that increased ERK signaling occurs via an association
between BRAF and CRAF and their ability to stimulate
ERK is dependent on CRAF activation [41]. It has been
demonstrated that p.Gly466Glu cells depend on CRAF for
ERK signaling: they induce strong CRAF activation and
CRAF depletion significantly suppresses ERK signaling [41].
PIK3CA helical domain mutants p.Glu542Lys,
p.Glu545Lys, and p.Gln546Lys and kinase domain mu-
tants p.Met1043Ile, p.His1047Arg, p.His1047Leu, andFigure 3 Distribution of KRAS, BRAF and PIK3CA mutations accordingp.His1047Tyr all display enhanced lipid kinase activity
compared to the wild-type p110α, and p.Glu542Lys, p.
Glu545Lys, and p.His1047Arg induce AKT phosphor-
ylation at higher levels than the normal protein
[42-48]. Furthermore, p.Glu545Lys and p.His1047Arg
promote cell growth and invasion in CRC cell lines,
and mutations p.His1047Leu and p.His1047Tyr induce
oncogenic transformation in primary cell cultures of
chicken embryo fibroblasts [44,46]. In CRC, Met1043
is less frequently altered than His1047 (0.8% vs 7.1%)
[49]. Amino acids 1043 and 1047 are located on the
same protein helix and probably affect protein function
by altering activation loop conformation, leading to
elevated kinase activity [42,50]. The above referred
helical domain mutations occur at residues involved in
the interaction with the adaptor protein and are
thought to abrogate its inhibitory effect by increasing
the positive charge on the surface of the helical
domain. It has also been demonstrated that p85 does
not inhibit these mutants in vitro [45,50]. Finally, the
Glu to Asp substitution in codon 545 has not been
functionally studied, but both amino acids involved are
polar and negatively charged, thus making it unlikelyto primary tumor site.
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p110α as those described above. In this study we also
observed that PIK3CA codon 545 substitutions account
for 9.8% of PIK3CA mutations in CRC [49] and, since the
carcinoma carrying the PIK3CA p.Glu545Asp muta-
tion did not present mutations in either KRAS or
BRAF, it is conceivable that this mutation confers some
selective advantage.
In six cases, we found two different mutations in the
various exons studied, most commonly coexistence of a
PIK3CA mutation with either a KRAS or a BRAF mutation.
Coexisting mutations of KRAS/BRAF and PIK3CA have
been reported in several studies [24,30,31,36], with PIK3CA
exon 20 mutations more frequently co-occurring with
mutations of unknown significance or with KRAS codon
146 mutations [24]. Additionally, we found one instance of
coexistence of the PIK3CA p.His1047Arg mutation with
the novel mutation BRAF p.Val471Ala, a conserved residue
of RAF proteins, having no functional studies available
to allow inferences on its oncogenic potential. Finally,
one case harbored two KRAS mutations, namely the
novel p.Glu49Lys and the p.Ala146Thr mutations. The
coexistence of two mutations in the same gene or in
different genes may be explained by a synergistic con-
tribution of both mutations to pathway activation or
the occurrence of each mutation in different subclones
as a result of tumor clonal divergence.
According to a recently published large multicentric
study involving retrospective mutation analysis on KRAS,
BRAF, NRAS, and PIK3CA in mCRC and the impact of
mutations in these genes on cetuximab treatment efficacy
[24], tumors with KRAS codon 61 mutations have lower re-
sponse rates and PIK3CA exon 20 mutations are associated
with a worse outcome after cetuximab treatment, with
NRAS mutations (codons 12, 13 and 61) being predictive of
nonresponse to this targeted therapy. On the other hand,
this retrospective study indicates that KRAS codon 146 and
PIK3CA codon 9 mutations do not affect cetuximab
efficacy. This study also confirmed the inefficacy of
cetuximab in patients with BRAF p.Val600Glu muta-
tions, with response rates of 8% vs 38% for BRAF
mutated and wild-type, respectively [24,25,27,28,51].
No associations with treatment response have been
published for BRAF exon 11 mutations or any other
KRAS exon 3 mutations besides those in codon 61,
essentially because they are rare. We could not make
an evaluation of the predictive value of these mutations
in our patients at the time of writing due to the low
number of mutated cases that have been treated with
cetuximab, but in face of the findings of De Roock
et al. [25] our mutation data indicates that at least
10.9% of our mCRC patients wild-type for KRAS codon
12 and 13 would not benefit from anti-EGFR targeted
therapy. Further prospective or functional studies willbe necessary to evaluate the predictive value of the
remaining mutations, including the novel KRAS and
BRAF mutations we here report.
Conclusions
About one fourth of mCRC cases wild-type for KRAS
codons 12 and 13 present other mutations either in
KRAS, BRAF, or PIK3CA, many of which may explain
the lack of response to anti-EGFR therapy observed in a
significant proportion of these patients.
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